Clover Biopharmaceuticals Ltd. · HKEX:2197
Clover Biopharmaceuticals — Corporate Update (September 2026)
25 slides from Clover Biopharmaceuticals's corporate update, September 2026
Slide 1: Preliminary Phase 2 Results (Australia): RSV + hMPV ± PIV3 Combination Vaccines
CLOVER BIO (2197 HK) CORPORATE OVERVIEW Preliminary Phase 2 Results (Australia): RSV + hMPV ± PIV3 Combination Vaccines RSV hMPV PIV3 September 2026
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate,"
Slide 3: Executive Summary
Executive Summary Clover is Developing Potential Global First-in-Class and Best-in-Class RSV + hMPV ± PIV3 Combination Vaccines (Phase 2 Data) with the Potential Differentiated Ability to Re-Vaccinate Individuals Previously Receiving Approved RSV Vaccines to Restore and Broaden Protection ‘Plug & Pl
Slide 4: Clover's Trimer-Tag Technology Platform for Vaccine Development
Clover’s Trimer-Tag Technology Platform for Vaccine Development ▪ Highly Differentiated Vaccine Technology Platform: The only technology platform globally for producing recombinant covalently-trimerized antigens utilizing a human-derived trimerization tag; the use of covalent bond enables stable nat
Slide 5: Trimer-Tag: A Safe, Potent & Validated Vaccine Platform
Trimer-Tag: A Safe, Potent & Validated Vaccine Platform Extensive Clinical Experience Globally Endorsed by Leading Scientific Community 40,000+ Doses Administered Across 9 Countries & 6 Continents Received US$ 397 Million Funding from to Support Experience in Broad Population Groups (Elderly,
Slide 6: RSV is a Validated Blockbuster Market; Expansion is Dependent on Addressing 2 Unmet Needs
RSV is a Validated Blockbuster Market; Expansion is Dependent on Addressing 2 Unmet Needs 2 Key Unmet Needs & Opportunities to Unlock RSV Market Expansion: RSV RSV Vaccines Have Generated >US$6.5 Billion Product Sales in First 3.5 Years of Launch (2023-1H26) Opportunity to Multiply Market Value if
Slide 7: $10 Billion+ Potential Peak Sales Globally for RSV Combo Vaccines with Ability to Re-Vaccinate
$10 Billion+ Potential Peak Sales Globally for RSV Combo Vaccines with Ability to Re-Vaccinate Illustrative Estimated Peak Annual Doses in the U.S. for RSV Combination Vaccines ≥15M $10 Billion+ Potential Global Peak Sales for RSV Doses/Year Combination Vaccines with the Ability to Re-Vaccinate (1)
Slide 8: Clover Phase 1 Initial Dose Trial Validated Clover's Approach to Pre-F
Aus Ph1 RSV Clover Phase 1 Initial Dose Trial Validated Clover’s Approach to Pre-F in 2024 (OCT-2024) Demonstrated Best-in-Class Combined Immunogenicity & Tolerability Profile as an Initial Dose in RSV Vaccine-Naïve Older Adults, for Non-Adjuvanted SCB-1019T (Clover RSV Pre-F) Head-to-Head Versus AS
Slide 9: Clover Phase 1 Re-Vaccination Trial Demonstrated Clover's Differentiated Ability to Boost
U.S. Ph1 RSV Clover Phase 1 Re-Vaccination Trial Demonstrated Clover’s Differentiated Ability to Boost (‘25-’26) ▪ 1.5-1.9x Higher Trends in RSV Neutralizing Antibody (Nab) Titers Observed for Clover Re-Vaccination H2H Versus GSK (AREXVY) ▪ Magnitude of Trend for NAb Benefit May be Able to Restore P
Slide 10: Clover Phase 1 Re-Vaccination Trial: Differentiated Ability to Boost
U.S. Ph1 RSV Clover Phase 1 Re-Vaccination Trial Demonstrated Clover’s Differentiated Ability to Boost (‘25-’26) Clover’s Differentiated Ability to Revaccinate May be Driven by: (1) No ‘Off-Target’ Anti-Tag Antibodies and (2) Better Antibody Quality, Demonstrating the Advantages of Clover’s Trimer-T
Slide 11: Phase 2 Combo Trial Initiated in Jan 2026; Preliminary Results in Sep 2026
RSV hMPV PIV3 Phase 2 Combo Trial Initiated in Jan 2026; Preliminary Results in Sep 2026 Australia Phase 2 RSV hMPV PIV3 Phase 2: RSV-hMPV-PIV3 Combination Vaccines SCB-1022 (RSV-hMPV) Phase 2 Data Strengthens Clover’s First-in-Class (FiC) Non-Adjuvanted Australia and Best-in-Class (BiC) Positioni
Slide 12: Preliminary Phase 2 Results – Best-in-Class Combo Breadth (No Immune Interference)
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Best-in-Class Combo Breadth (No Immune Interference) Phase 2 Potential Best-in-Class Breadth of NAb Responses, with No Immune Interference for Combos Matches Approved Comparator (GSK) with No Interference from hMPV/PIV3 Potential BiC Responses
Slide 13: Preliminary Phase 2 Results – Best-in-Class hMPV
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Best-in-Class hMPV Phase 2 Potential Best-in-Class hMPV Structure & Functional Immune Responses/Breadth hMPV hMPV Pre-F Antigens: hMPV Neutralizing Antibodies (NAbs) Cryo-EM Structures hMPV-A hMPV-B NAb Titers (GMTs) NAb Fold Rises (GMFRs) Vice
Slide 14: Preliminary Phase 2 Results – Best-in-Class PIV3
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Best-in-Class PIV3 Phase 2 PIV3 PIV3 Neutralizing Antibodies (GMFR) Best-in-Class PIV3 Responses, Potentially Providing Breadth Beyond RSV + hMPV Low Baseline ▪ ~5-Fold Increases in PIV3 nAbs in participants with low pre-existing baseline PIV3
Slide 15: Preliminary Phase 2 Results – Safety & Tolerability
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Safety & Tolerability Phase 2 Potential Best-in-Class Safety & Tolerability Profiles for SCB-1022 and SCB-1033 Local & Systemic AEs for SCB-1022 (RSV-hMPV) and SCB-1033 (RSV-hMPV-PIV3) were Generally Mild and Comparable to Prior Phase 1 Results
Slide 16: Preliminary Phase 2 Results – Respiratory Tract Infections Reported
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Respiratory Tract Infections Reported Phase 2 Fewer Respiratory Tract Infections for SCB-1022/1033 vs. Placebo; No Disease Enhancement Signal Observed ▪ No Prospective Monitoring/Sequencing of Infection Cases Conducted in the Study (1) ▪ Respir
Slide 17: Preliminary Phase 2 Results – Executive Summary
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Executive Summary Phase 2 Positive Phase 2 Results for RSV+hMPV±PIV3 Combos Significantly De-Risk Future Late-Stage Development Immunogenicity: Best-in-Class Neutralizing Antibody (NAb) Responses & Breadth Combined Across RSV + hMPV ± PIV3 No
Slide 18: Clover is Developing Potential Best-in-Class RSV+hMPV±PIV3 Combination Vaccines
Clover is Developing Potential Best-in-Class RSV+hMPV±PIV3 Combination Vaccines, with the Differentiated Ability to Effectively Re-Vaccinate Individuals Previously Receiving Approved RSV Vaccines to Both Restore & Broaden Protection Positive Phase 2 Data for Clover’s Differentiated RSV+hMPV±PIV3 C
Slide 19: Trimer-Tag Platform Can Address ~75% of Viral Respiratory Disease Burden in Elderly
Trimer-Tag Platform has Potential To Address ~75% of Viral Respiratory Disease Burden in Elderly Annual Disease Burden of Respiratory Viruses Trimer-Tag Platform Opportunity for Respiratory Combination Vaccines in Elderly in Elderly Population in U.S. (Est. Hospitalizations per 100,000 Persons) SCB-
Slide 20: Appendix
Appendix Page 20
Slide 21: Efficacy of Protein-Based RSV Vaccines is Durable for Up to 2 Seasons
Efficacy of Protein-Based RSV Vaccines (Initial Dose) is Durable for Up to 2 Seasons; RSV Re-Vaccination is Needed to Restore Protection Initial Dose: Monthly Vaccine Efficacy Point Estimates (RSV LRTD ≥2 Symptoms) (1,2,3) 90% GSK Season 1 Efficacy: 83% 80% ➢ Protein-Based RSV Vaccines Appear to hav
Slide 22: No ACIP Recommendation for RSV Re-Vaccination; Clinical Data Not Supportive
However, No ACIP Recommendation for RSV Re-Vaccination; RSV Clinical Data is Not Supportive with Subpar Boosting Results for GSK & Pfizer ▪ GSK / Pfizer: Re-Vaccination at 1-3 Year Intervals Only Transiently Boosts RSV NAbs Back to ~45-65% of Peak Levels (1,2) and is Not Associated with Any Benefit
Slide 23: Unmet Need and Opportunity to Broaden Protection Beyond RSV to hMPV ± PIV3
Significant Unmet Need and Opportunity to Broaden Protection & the RSV hMPV PIV3 Associated Impacts on Chronic Diseases Beyond RSV to hMPV ± PIV3 Via Combo Vaccine Established Ability of Respiratory Vaccines (RSV, Flu) to Reduce Worsening of Chronic Diseases (COPD, Asthma, CVD, CLD, etc.) (1,2,3,4);
Slide 24: Comparison: Clover Re-Vaccination Phase 1 Study to Initial Dose Study
RSV COMPARISON: Clover Re-Vaccination Phase 1 Study to Clover Initial Dose Study Phase 1 Study Comparison Across Trials with Samples Tested Contemporaneously in the Same Lab: ▪ RSV NAbs Restored to ~120% of Initial Dose Peak Levels (Cross-Trial Comparison); Only ~75% for Homologous AREXVY RSV Neutra
Slide 25: Preliminary – Antibody Titers Versus Phase 1
Australia RSV hMPV PIV3 Preliminary Phase 2 Results – Antibody Titers Versus Phase 1 Phase 2 Phase 2 Antibody Titers (GMTs) were Comparable (RSV, PIV3) or Trended Higher (hMPV) Than Phase 1 Results PreF-Specific Antibody Titers (Site Ø) RSV Titers (GMTs) hMPV Titers (GMTs) PIV3 Titers (GMTs) PHASE 2
Clover Biopharmaceuticals — Corporate Update (September 2026) on 6ix